OCALA, Fla., April 16, 2026

AIM ImmunoTech Inc. has announced significant progress in its oncology pipeline, entering a pivotal Phase 3 development stage for Ampligen®, a novel immunotherapy targeting late-stage pancreatic cancer, one of the most aggressive and difficult-to-treat malignancies. Backed by positive Phase 2 clinical signals, Orphan Drug designations in the U.S. and EU, and a strong global intellectual property portfolio, the company is positioning Ampligen as a potential breakthrough therapy in oncology.

Strong Clinical Signals Support Phase 3 Advancement

The planned Phase 3 program is supported by encouraging clinical data from multiple studies, including a Dutch government-approved Named Patient Program and the ongoing Phase 2 DURIPANC trial, which evaluates Ampligen both as a monotherapy and in combination with checkpoint inhibitors. Results have demonstrated improvements in progression-free survival and overall survival, along with a favorable safety profile, reinforcing the therapy’s potential to address a significant unmet need.

Notably, over 100 patients have been treated with Ampligen across studies, with consistent outcomes supporting its role in enhancing immune response against tumors. These findings significantly de-risk the transition into late-stage clinical development, making Ampligen a promising candidate in the fight against pancreatic cancer.

Innovative Mechanism and Strategic Collaborations

Advertisement

cGxPJobs Banner

Ampligen is a selective TLR3 agonist immunotherapy, designed to activate the innate immune system and improve tumor responsiveness to treatment. This mechanism enables its use both as a standalone therapy and in combination with leading immuno-oncology agents, including checkpoint inhibitors from major pharmaceutical companies.

To support its Phase 3 program, AIM ImmunoTech has partnered with the PPD clinical research business of Thermo Fisher Scientific, bringing advanced clinical trial design expertise to optimize development. This collaboration underscores the company’s commitment to high-quality, GxP-compliant clinical execution, ensuring robust data generation and regulatory readiness.

Orphan Drug Status and Global IP Strengthen Market Potential

Ampligen has received Orphan Drug designation in both the United States and Europe, providing key regulatory advantages such as market exclusivity, reduced development costs, and accelerated approval pathways. The company is also pursuing similar designation in Japan, further expanding its global regulatory footprint.

In parallel, AIM ImmunoTech has strengthened its intellectual property portfolio, including a recently approved Japanese patent extending protection through 2039, alongside existing patents in the U.S. and Europe. This robust IP position supports long-term commercial potential across major global markets, reinforcing Ampligen’s strategic value.

Implications for Oncology Innovation and GxP Development

The advancement of Ampligen into Phase 3 reflects broader trends in the biopharma industry toward immune-based therapies and combination treatment strategies for complex cancers. With pancreatic cancer projected to become the second leading cause of cancer-related deaths in the U.S., the need for innovative therapies remains urgent.

AIM ImmunoTech’s approach highlights the importance of integrating clinical evidence, regulatory strategy, and manufacturing excellence under GxP frameworks, ensuring both scientific rigor and compliance. The company’s focus on data-driven development and global regulatory alignment positions Ampligen as a potential game-changing therapy in oncology.

The AIM ImmunoTech Ampligen program represents a critical milestone in pancreatic cancer research, combining strong clinical evidence, innovative immunotherapy mechanisms, and strategic partnerships to advance into late-stage development. With Phase 3 planning underway and regulatory incentives in place, Ampligen has the potential to transform treatment outcomes in one of the most challenging cancer indications, offering new hope for patients and reinforcing the company’s position in the global biopharma landscape.

Source: AIM ImmunoTech Inc press release